The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
Sponsor: Heba M. Ismail • ClinicalTrials.gov ID: NCT05414409
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
Ovwerweight and obesity prevalence in persons with T1D has increased, which further complicates management and risk for complications. The proposed study is relevant to public health because it helps us understand the role of the gut microbiome in disease pathophysiology in T1D youth with overweight and obesity as well as potential mechanisms to modify disease.
Interventions
-
Metformin
(Drug)
Metformin is an oral medication that improves insulin sensitivity.
Eligibility criteria
Conditions
Locations
- Indiana University School of Medicine — Indianapolis, Indiana, United States
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record